Skip to content

LSD research published in 2022

Page 5 of 5: studies 81 to 85 of 85, newest first. Back to the LSD overview

Studies

Psychedelic-Assisted Therapy for Substance Use Disorders and Potential Mechanisms of Action.

Current Topics in Behavioral Neurosciences 2022 Nathalie M. Rieser, Marcus Herdener, Katrin H. Preller

Substance use disorders (SUD) represent a significant public health issue with a high need for novel and efficacious treatment options. In light of this high unmet need, recent results reporting beneficial outcomes of psychedelic-assisted therapy in SUD are particularly relevant. However, several questions remain with regard to this treatment approach. The clinical mechanisms of action of...

Lysergic Acid Diethylamide Produces Anxiogenic Effects in the Rat Light/Dark Test and Elevated Plus Maze

Psi Chi Journal of Psychological Research 2022 Catherine N. Conway, Lisa E Baker 6 citations

Recent clinical trials indicate favorable therapeutic outcomes of psychedelic-assisted psychotherapy for anxiety and treatment-resistant depression. Whereas the neurobiological systems underlying these effects are not well understood, animal behavioral models can serve to investigate these mechanisms. For the current study, we implemented 2 rodent models predictive of anxiolytic drug effects, a...

Effect of -NBOMe Compounds on Sensorimotor, Motor, and Prepulse Inhibition Responses in Mice in Comparison With the 2C Analogs and Lysergic Acid Diethylamide: From Preclinical Evidence to Forensic Implication in Driving Under the Influence of Drugs.

Frontiers in Psychiatry 2022 Micaela Tirri, Sabrine Bilel, Raffaella Arfè et al. 17 citations

In the last decade, the market for new psychoactive substances has been enriched by numerous psychedelic phenethylamines, which mimic the psychoactive effect of lysergic acid diethylamide (LSD). In particular, the -NBOMe series, which are more potent than their 2C compounds analogs, are considered worthy substitutes for LSD by users. The purpose of this study was to assess the effects of...

Human behavioral pharmacology of psychedelics.

Advances in pharmacology (San Diego, Calif.) 2022 Justin C Strickland, Matthew W Johnson 13 citations

The past decade has witnessed a rapid growth of research on the basic science and clinical understanding of psychedelics. This chapter provides an overview of the human behavioral pharmacology of psychedelics focusing on three prototypic classic psychedelics-psilocybin, lysergic acid diethylamide (LSD), and dimethyltryptamine (DMT). A brief historical overview of the classic psychedelics and...

United States National Institutes of Health grant funding for psychedelic-assisted therapy clinical trials from 2006-2020.

International Journal of Drug Policy 2022 Brian S. Barnett, Sloane E Parker, Jeremy Weleff 57 citations

Medicine is currently experiencing a "psychedelic renaissance", said by many to have commenced in 2006. Since then, clinical trials have consistently demonstrated promising findings for psychedelic-assisted therapies in the treatment of various mental health conditions and addictions. While most of this work has been privately funded, governmental biomedical research funding bodies in countries...